Начало › Рак на белия дроб с недребноклетъчен тип › Калифорния › San Francisco
Клинични проучвания за Рак на белия дроб с недребноклетъчен тип в San Francisco, CA
36 проучвания за Рак на белия дроб с недребноклетъчен тип търсят участници в обекти в и около San Francisco (в радиус от около 30 мили). Отворете проучването, за да видите кой може да участва и как да се свържете с екипа.
Официален текст на проучването (английски)
Търсите участници за проучване? Представяме го в началото на тази страница — $99 за 30 дни →
A Study of ZW251 in Participants With Advanced Solid Tumors
Набиране на участнициФаза 1
- UCSF Comprehensive Cancer Center, San Francisco
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Набиране на участнициФаза 3
- California Pacific Medical Center-Pacific Campus, San Francisco
- Kaiser Permanente-San Francisco, San Francisco
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Набиране на участнициФаза 3
- UCSF Medical Center at Mission Bay ( Site 0178), San Francisco
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Набиране на участнициФаза 3
- Kaiser Permanente-San Francisco, San Francisco
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Набиране на участнициФаза 3
- San Francisco Oncology Associates ( Site 0066), San Francisco
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Набиране на участнициФаза 2
- UCSF Zuckerberg San Francisco General Hospital, San Francisco
Intratumoral N17350 in Advanced Solid Tumors
Набиране на участнициФаза 1/2
- University of California, San Francisco, San Francisco
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Набиране на участнициФаза 3
- Research Site, San Francisco
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
Набиране на участнициФаза 3
- UCSF Health - UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Набиране на участнициФаза 3
- University of California San Francisco, San Francisco
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Набиране на участнициФаза 1/2
- University of California, San Francisco (UCSF), San Francisco
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Набиране на участнициФаза 2/3
- San Francisco Veterans Affairs Medical Center, San Francisco
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
Набиране на участнициФаза 1/2
- UCSF Helen Diller Medical Center at Parnassus Heights - Neurology, San Francisco
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Набиране на участнициФаза 3
- California Pacific Medical Center, San Francisco
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Набиране на участнициФаза 1
- University of California San Francisco, San Francisco
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
Набиране на участнициФаза 1
- University of California San Francisco, San Francisco
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Набиране на участнициФаза 1/2
- University of California San Francisco, San Francisco
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Набиране на участнициФаза 3
- UCSF Medical Center-Mission Bay, San Francisco
Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer
Набиране на участнициФаза 2
- University of California San Francisco, San Francisco
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Набиране на участнициФаза 1/2
- UCSF Medical Center - Mission Bay, San Francisco
Biomarkers for Risk Stratification in Lung Cancer
Набиране на участнициНаблюдателно проучване
- Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco
- San Francisco VA Medical Center, San Francisco
- University of California, San Francisco, San Francisco
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Набиране на участнициФаза 2
- California Pacific Medical Center-Pacific Campus, San Francisco
- Kaiser Permanente-San Francisco, San Francisco
- Veterans Affairs Medical Center - San Francisco, San Francisco
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Набиране на участнициФаза 1
- University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Набиране на участнициФаза 2
- California Pacific Medical Center-Pacific Campus, San Francisco
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Набиране на участнициФаза 2/3
- Kaiser Permanente-San Francisco, San Francisco
- Veterans Affairs Medical Center - San Francisco, San Francisco
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Набиране на участнициФаза 2
- California Pacific Medical Center-Pacific Campus, San Francisco
- Kaiser Permanente-San Francisco, San Francisco
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Набиране на участници
- Zuckerberg San Francisco General, San Francisco
- Kaiser Foundation Research Institute, San Francisco
- University of San Francisco, San Francisco
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Набиране на участнициФаза 2
- UCSF Medical Center at Mission Bay, San Francisco
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Набиране на участнициФаза 1/2
- University of California at San Francisco, San Francisco
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Набиране на участнициФаза 1/2
- University of California San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center, San Francisco
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Набиране на участнициНаблюдателно проучване
- Kaiser Permanente-San Francisco, San Francisco
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
Набиране на участнициФаза 1/2
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Набиране на участнициНаблюдателно проучване
- Massive Bio SYNERGY-AI site, San Francisco
A Study of NX-1607 in Adults With Advanced Malignancies
Набиране на участнициФаза 1
- University of California, San Francisco, San Francisco
A Multicenter Cancer Biospecimen Collection Study
Набиране на участнициНаблюдателно проучване
- Curebase, San Francisco
A Study of IBI363 in Subjects with Advanced Solid Malignancies
Набиране на участнициФаза 2
- University of California, San Francisco (UCSF), San Francisco
Проучвания за Рак на белия дроб с недребноклетъчен тип в други градове
- Houston, TX145 проучвания
- New York City, NY121 проучвания
- Arlington, VA104 проучвания
- Nashville, TN97 проучвания
- Boston, MA90 проучвания
- Los Angeles, CA87 проучвания
- St. Louis, MO73 проучвания
- Chicago, IL61 проучвания
- Baltimore, MD60 проучвания
- San Antonio, TX59 проучвания
- Columbus, OH57 проучвания
- Washington, DC55 проучвания
Други проучвания в San Francisco
- Рак на простатата45 проучвания
- Рак на гърдата43 проучвания
- Рак (всички видове)35 проучвания
- Сърдечна недостатъчност29 проучвания
- Метастатичен рак28 проучвания
- Рак на белия дроб22 проучвания
- Меланом22 проучвания
- Рак на панкреаса20 проучвания
- Рак на яйчниците19 проучвания
- Колоректален рак18 проучвания
- Сърдечно-съдово заболяване18 проучвания
- Глиобластом17 проучвания
От ClinicalTrials.gov, данни към 6.10.2026 г.. Всяко проучване има свои критерии за участие; екипът на проучването определя кой може да се включи.